Eloxx Pharmaceuticals, Inc. quarterly report, Q1 FY2015

Filing identity and reporting period

Important mismatch: The supplied filing is Sevion Therapeutics, Inc. (formerly Senesco Technologies, Inc.), not Eloxx Pharmaceuticals, Inc. It is a Form 10-Q for the three months ended September 30, 2014, filed November 14, 2014. Given the company’s June 30 fiscal year-end, this is the first quarter of fiscal 2015; the request metadata’s company name and “2014 Q1” do not match the filing.

Sevion describes itself as a development-stage biotechnology company pursuing antibody-based therapies and gene-regulation technology. Fabrus, acquired in May 2014, is included in the current-quarter results but not the prior-year comparison. The company changed its name on September 29, 2014.

Financial results and liquidity

Cash and cash equivalents were $3.837 million at September 30, down from $6.111 million at June 30, 2014. Working capital was $2.356 million. Investing activities used $0.335 million; financing activities provided no cash. Total liabilities were $5.707 million, including $1.687 million in current liabilities and a $3.920 million deferred tax liability. The balance sheet does not list conventional borrowings. Profit margins are not meaningful given zero current-period revenue and operating losses.

Material changes and unusual items

• Net loss increased $3.399 million, or 190.5%, year over year, primarily due to higher R&D expense and patent impairment; lower G&A partly offset the increase.
• The $2.291 million patent impairment related to Factor 5A intellectual property. The company also expensed $669,750 of unused clinical-trial materials after putting that program on hold.
• R&D expense rose 161.4%, in part because of Fabrus, higher staffing and research costs, and the write-off of trial materials. G&A fell 9.6%.
• Revenue fell from a $100,000 agricultural-license milestone payment in the prior-year quarter to zero. Future milestones and royalties depend on partners’ development and commercialization efforts, and timing is uncertain.
• Basic weighted-average shares increased to 13.846 million from 2.308 million; the filing reports 7.238 million warrants and 0.970 million options outstanding at quarter-end, in addition to convertible preferred shares.

Outlook, risks, and contingencies

Management estimated that September 30 cash would fund expenses through at least March 31, 2015, but said additional capital would be needed. Potential sources include equity or debt financing, warrant exercises, and licensing arrangements; none is assured on acceptable terms. The filing cites recurring losses and negative operating cash flow as raising substantial doubt about the company’s ability to continue as a going concern, and notes that the prior-year auditor’s report included a going-concern explanatory paragraph.

After quarter-end, on October 22, the board suspended Factor 5A development, citing limited capital and the totality of Phase 1b/2a safety and efficacy data. The trial had completed dosing; reported dose-limiting toxicities included a Grade 4 infusion reaction and Grade 4 neutropenia. The company said it was considering reformulation, a partnership or sale, or discontinuation. It also planned to focus intellectual-property development on human-health targets, close its Bridgewater office, consolidate operations in San Diego, and terminate the University of Waterloo research agreement effective December 31, 2014.

Management identified financing availability, clinical and preclinical outcomes, regulatory approval, intellectual-property protection, competition, third-party research/manufacturing reliance, and potential dilution as significant risks. No legal proceedings or material changes to contractual obligations were reported in the quarter. The filing states that disclosure controls were effective and that there were no material changes in internal control over financial reporting.

Important facts for investors to verify

• Confirm the intended issuer and period: this is Sevion Therapeutics’ September 30, 2014 10-Q, not an Eloxx Pharmaceuticals filing.
• Review the Factor 5A program’s post-quarter suspension, trial safety and efficacy disclosures, and the resulting patent impairment.
• Assess the cash runway, planned financing needs, going-concern language, and whether funding or licensing transactions were subsequently secured.
• Reconcile a cash figure inconsistency: the balance sheet and liquidity discussion report $3.837 million at September 30, but one risk-factor passage says $3.387 million.
• Consider potential dilution from outstanding warrants, options, and convertible preferred stock, alongside the reported limited trading market.